Human stromelysin-3 (ST3) is a matrix metalloproteinase (MMP) t h a t has been implicated in cancer progression and in various tissue remodeling processes. Unlike most MMPs, ST3 is characterized by a distinct substrate specificity, a specific regulation, and is not directly involved in extracellular matrix degradation. In the present study, w e have identified an additional ST3 gene promoter that is accessible t o nuclear factors such as C/EBP and RARs. This human specific p r o m o t e r is inducible and controls the expression of a novel ST3 transcript called the β-ST3 that is expressed in cultured cells and in placenta. This transcript encodes a 40 kDa ST3 isoform that lacks both the signal peptide common to all secreted MMPs and the prodomain that normally maintains enzyme latency. Consistent with the lack of a signal peptide, the β-ST3 was found to be intracellular. The relative amount of t h e extracellular α-ST3 isoform was about twenty fold higher than that of the intracellular ST3 isoforms, as estimated by Western blot analysis. Furthermore, recombinant β-ST3 produced in Escherichia coli exhibits a proteolytic activity against α 1-proteinase inhibitor, a s u b s t r a t e previously shown to be inactivated by the α-ST3. Therefore, while i t was thought that all MMPs were synthesized as inactive zymogens a n d functioned extracellularly, this is the first MMP isoform reported that is generated by alternative promoter usage and to be directly translated as an active enzyme. Although the intracellular function of the β-ST3 remains to be investigated, these data support the idea that t h e functions of MMPs are not restricted to the extracellular space.
INTRODUCTION
The matrix metalloproteinases (MMPs) belong to a well conserved family of matrix degrading endopeptidases that are implicated i n physiological processes associated with tissue remodeling (1) . They a r e divided in four major subgroups in which most members are organized into three basic and well-conserved domains: the pro-peptide, t h e catalytic domain and the hemopexin-like domain (2) . Their catalytic activity is regulated at the levels of transcription, secretion, activation and inhibition. All MMPs are produced in a latent inactive form a n d their activation requires removal of the propeptide. While t h i s activation occurs for most following their secretion, ST3 and m e m b r a n e type-MMPs have a specific furin recognition site at the end of t h e i r propeptide that mediates their activation within the cell (3, 4) . Although related by sequence to MMPs, at a functional level, the human ST3, i n contrast to the mouse ST3, does not degrade components of t h e extracellular matrix (ECM) (5) . Nevertheless, its catalytic activity h a s been demonstrated against insulin-like growth factor (IGF) binding protein-1 (6) and serine proteinase inhibitors (serpins) (7) . The f o r m e r substrate suggests that ST3, by controlling the availability of IGF, plays a role in processes such as cell proliferation and/or differentiation. T h e degradation of serpins suggests an indirect role for ST3 in ECM t u r nover through the degradation of the inhibitors of this process. ST3 w a s initially identified in the stromal compartment of breast carcinomas (8) . Furthermore, ST3 has been shown to be one of the rare MMPs for which a significant correlation has been demonstrated between its expression in tumors and a poor prognosis in patients with breast cancer (9,10). I t s expression is also associated with the invasion and aggressiveness of most types of human carcinomas (11) . Accordingly, ST3 promotes b o t h tumor take in mice and homing of malignant cells (12, 13) . Taken together, a number of clinical and experimental investigations suggested that ST3, as other MMPs (14) (15) (16) , may represent an attractive target f o r therapeutic approaches directed against the stromal compartment of human carcinomas and, to this end, specific inhibitors of ST3 have b e e n designed (17) . Like other MMPs, ST3 is expressed during wound healing (18) , mammary gland involution (19) , cycling endometrium (20) a n d development (21) . However, although in vivo studies have emphasized the contribution of this enzyme in functions such as cell migration, apoptosis or in tumor progression, the mechanisms and the factors controlling its cell specific expression remain poorly understood. At t h e cellular level, tumor-stroma coculture assays have provided evidence that the expression of ST3 in fibroblasts requires direct contact b e t w e e n fibroblasts and cancer cells (22) . In contrast to this, the induction of other MMPs such as MMP-1 in fibroblasts is mediated by a soluble factor produced by cancer cells (23) . At the molecular level, ST3 is induced by basic fibroblast growth factor (8) , thyroid hormone (24) a n d phorbol esters (25) , whereas it is repressed by progesterone (20) . I n addition, while the expression of MMPs is usually repressed by retinoic acid (RA) (26) , the expression of ST3 has been shown to be induced b y RA through a retinoic acid responsive element present in its proximal promoter and interacting with retinoic acid receptor/retinoid X receptor heterodimers (27) . Taken together, these observations indicate that ST3 shares, to some extent, a similar expression pattern with other MMPs, but also differs strongly from most of them in its activation process, its catalytic activity and its specific regulation. In the present study, we have looked for additional regulatory sequences that could control the cell specific expression of ST3 b y mapping chromatin accessible regions. This approach has allowed us t o identify an additional ST3 isoform that differs from all MMPs described thus far. Indeed, this isoform is directly translated into an active f o r m and is not secreted. Our findings provide new insights into t h e regulation of ST3 and highlight hitherto unknown intracellular MMP functions.
EXPERIMENTAL PROCEDURES

Cell culture
The rhabdomyosarcoma cell line (RD) and the SL-6 NSCLC cell line w e r e maintained in monolayer culture in Dulbecco's modified Eagle's m e d i u m supplemented with 5% calf serum, and RPMI 10% FCS, as previously described (22, 25) . HeLa cells and COS-1 cells were cultured in the s a m e medium in the presence of 10% and 5% fetal calf serum, respectively. I n selected experiments, cells were exposed to 20 ng/ml TPA (Sigma), 1 µM 9-cis-retinoic acid (provided by P.F. Sorter, Hoffmann-La Roche, Nutley, N.J.), or to the MMP inhibitors BB94 (British Biotech, Oxford, UK) (28) and RXPO3 (CEA, Saclay, France) (17) .
Analysis of DNase I hypersensitive sites.
Nuclei preparation and DNase I hypersensitive site mapping w e r e performed, as described previously (25) . Briefly, 100 µg of purified nuclei were resuspended at a concentration of 0.5 µg DNA /µ l a n d digested with 3, 6 or 12 units of DNase I (grade I, Boehringer Mannheim). DNA was extracted and 20 µg was digested w i t h appropriate restriction enzymes. Southern blot analysis was p e r f o r m e d using genomic probes generated near the end of the restriction fragments of interest.
In vitro DNase I footprinting. Two overlapping DNA fragments of 635 bp and 452 bp and extending respectively from nucleotides -782 to -148 and from nucleotides -2 4 7 to +205 relative to the second transcription start site (+2) w e r e generated by PCR. After subcloning, the resulting fragments w e r e isolated in order to label their coding and non-coding strands with t h e Klenow enzyme. Purified probes were incubated with nuclear extracts and binding was performed before analyzing the DNA on a denaturating sequencing gel, as previously described (25) .
Access RT-PCR System (Promega) using the avian myeloblastosis v i r u s reverse transcriptase and the Tfl DNA polymerase. The 2 primers 5 ' -GGCTTCCTGACCACAGCCTCACCTTTG-3' (XU112) and 5 ' -GCGCAGTCTAGAGCCCTGCCTGCCAGGATG-3' (XU113, with restriction site underlined) designed from the 5' exon of the β-ST3 transcript w e r e used with several 3' primers complementary to sequences in exon 3 ( 5 ' -TGGCGTCACATCGCTCCATACCTTTAG-3', XY79), exon 4 ( 5 ' -CTGGTCATCCCCGATAGTCCAGGTCTCATC-3', XV153), exon 5 ( 5 ' -CTCAGTGGGTAGCGAAAGGTGTAGAAG-3', XY78) and in the 3'-UTR of exon 8 (5'-CGGGCATCTAGACCATGGTCAGAGGAAAGTG-3', YA161; 5 ' -CGGGGTACCTGGCCATGGGTCTCTAGCCTGATATTC-3', XV226; 5 ' -GGTCCCAAGACTGCCCTTCCTCTTAAG-3', XV225), exons n u m b e r e d according to the structure of the ST3 gene originally reported (29) . T h e α-ST3 transcript was also analyzed by using some of these 3 ' -p r i m e r s with a 5' primer (5'-CGATGCTGCTGCTGCTGCTCCAG-3', YA160) designed from the sequence of the first exon (1α) of the α-ST3 cDNA.
Mapping the transcription start site and quantification of t w o ST3 transcripts
The [γ-32 P] dATP end-labeled antisense primer YA45 (5'-TCTCGGCATGGAGGTGGTGGACGTC-3'), designed from the sequence of t h e second exon, common to both α -and β-ST3 transcripts, was annealed t o 2 µg RNA extracted from COS-1 cells or COS-1 cells transfected with t h e β-ST3 cDNA under the control of its own promoter (P2-β-ST3 construct). The same primer was annealed to 10 µg RNA extracted from RA-treated RD cells or human placenta. Reverse transcription was performed a n d the resulting extended products were analyzed on a sequencing gel, a s previously described (29) . Dideoxy sequencing reactions w e r e performed with the same primer by using the P2-β-ST3 construct as a DNA template allowing direct reading of the 5'-end sequence of the β -ST3 transcript.
Western blot analysis
Conditioned media were collected from cells cultured in serum f r e e conditions and analyzed, as previously described (5) . Cells w e r e resuspended in lysis buffer (50 mM Tris-HCl, pH 6.8, 150 mM NaCl, 1 0 mM EDTA, 2% SDS, 2.5% β -mercaptoethanol and a proteinase inhibitor mixture (Roche Molecular Biochemicals) including pepstatin, antipain, aprotinin, leupeptin and chymostatin at 2.5 mg/ml each) and sonicated.
The cell lysates from transfected COS-1 cells (0.2 µg), SL-6 cells (200 µg) and RD cells (100 µg) were separated on 10-12.5% SDS-PAGE gels u n d e r reducing conditions and analyzed by Western blot with the monoclonal antibodies 5ST4A9 (30) and 1G4 (31) .
Construction of luciferase reporter plasmids.
Luciferase constructs containing various lengths of the second ST3 promoter (P2) were generated by PCR amplification from a 5.5 kb Xho I/Not I genomic template (29) . Primers were designed to generate PCR products with Kpn I at their 5'-end and Xho I at their 3'-end allowing their insertion into the firely luciferase reporter plasmid (pGL3-Basic, Promega Corp.). The various constructs with their 5' and 3' ends defined by their position relative to the transcription start site are the following: 1-ST3-luc (-726 to +278), 0.5-ST3-luc (-459 to +8), 0.3-ST3-luc (-325 t o +8), 0.06-ST3-luc (-59 to +8) and 0.9-ST3-luc (-782 to -148).
Transient transfection and Luciferase assay.
RD cells were transiently transfected in 6-well plates by the calcium phosphate procedure, as previously described (25) using 2.5 µg of luciferase reporter plasmids and 0.25 µg of pCH110 plasmid as a n internal control for transfection efficiency. Transfections w e r e performed in triplicate and repeated three or four times. Results w e r e normalized for protein content (light units/µ g of protein).
cDNA constructs and expression in COS-1 cells
The P2-β-ST3 construct including the β-ST3 cDNA under the control of its own promoter (P2) was generated from two overlapping PCR products (Fig. 4A) . The first PCR product (-59 to +141) includes a genomic sequence from the second promoter (P2) to the most 5' exon (called exon -1β) and was amplified by using the 1-ST3-luc construct a s genomic template with 5 ' -CGGGGTACCGTGTAGGTTGTTAAAAATTACTGCTGTCTTACTTC-3' ( w i t h restriction site underlined) as 5' primer (XS249) and 5 ' -GCAGAGCCACGATCCAGGCAGTG-3' as a 3' primer. The second PCR product (β-ST3-cDNA) includes a cDNA sequence from the same exon -1 β to the 3'-untranslated region (exon 8) and was generated by RT-PCR by using RNA extracted from RD cells exposed to RA with 5 ' -GGCTTCCTGACCACAGCCTCACCTTTG-3' as a 5'-primer and 5 ' -GGTCCCAAGACTGCCCTTCCTCTTAAG-3' as a 3' primer. Both DNA fragments were annealed by denaturation at 94°C for 2 min followed b y renaturation at 68°C for 2 min and the resulting heteroduplexes w e r e extended with DNA polymerase I. PCR was carried out by using the 5 ' primer XS249 containing a Kpn I restriction site, and a 3' primer 5 ' -CGGGCATCTAGACCATGGTCAGAGGAAAGTG-3' containing a Xba I site a n d the PCR product was cloned into the pGL3-Basic vector (Promega, Corp.) restricted by Xba I and Kpn I, thereby replacing the luciferase cDNA.
Purification of recombinant ST3 isoforms
The cDNA encoding the α-ST3 proenzyme (PE) or the mature enzyme (E) including the catalytic and the hemopexin domains (residues Phe98 t o Leu488) were cloned into the pSG5 vector for expression in COS-1 cells or in pET-3b for expression in Escherichia coli BL21 (DE3)pLysS, a s previously described (5) . The cDNA fragment encoding the β-ST3 isoform (residues Met 130 to Leu488) was generated by PCR using t h e α -ST3 precursor form (PE) cDNA as template with 2 sets of primers. T h e 5'-primers 5'-GAGAGAATTCATGGCAGAGGCCCTAAAG-3' and the 3 ' -primer 5'-GAGAGAATTCCTATCAGAGGAAAGTGTTGGC-3' were used t o clone into the Eco RI restriction site of pSG5, while the 5'-primer 5 ' -GCGGCAGACCATGGCAGAGGCCCTAAAGGTATG and the 3'-primer 5 ' -CGGGCATCTAGACCATGGTCAGAGGAAAGTG-3' were used to clone into the Nco I restriction site of the pET-15b vector (Novagen). This pET15b-β-ST3 was modified by site-directed mutagenesis to substitute t h e Glu at position 87 in the β-ST3 (position 216 in the α-ST3) by Ala b y using the QuickChange TM mutagenesis kit (Stratagene) and the t w o primers 5'-CAGGTGGCAGCCCATGCATTTGGCCACGTGCTG-3' and 5 ' -CAGCACGTGGCCAAATGCATGGGCTGCCACCTG-3'. The E. coli strain BL21(DE3) was then transformed with pET-15b-β-ST3 and pET-15b-β-ST3m87 and recombinant proteins were purified and analyzed by Nterminal amino acid sequencing, as previously reported (5, 32) .
Enzymatic activity of recombinant ST3 isoforms
The activities of α-ST3 (E), β-ST3 and β-ST3m87 were quantified using an indirect test based on their ability to inactivate α -antitrypsin (α 1 -P I or α 1-proteinase inhibitor), an inhibitor of α -chymotrypsin (α-CT). T h e activity of α-CT (1 µg) against a synthetic peptide substrate w a s evaluated in the presence of 1 µg of α 1-PI incubated with or without 9 purified recombinant ST3 isoforms (1 µg), as previously described (32, 33) . The cleavage of the colorless substrate yields to a yellow product whose optical density is quantified using a Beckman DU640 spectrophotometer.
RESULTS
Identification
of accessible ST3 5'-flanking sequences b y mapping DNase I hypersensitive sites Important regulatory sequences, such as promoter, enhancer, or cell specific genomic regions are nucleosome free regions and, as such, a r e more accessible to a variety of transcription factors. These sequences are usually associated with the presence of DNase I hypersensitive sites (DHS) (34). In order to identify novel regulatory sequences, we h a v e mapped DHS present in a 5.3 kb Sac I genomic fragment that can b e divided in two regions of 3.7 kb and 1.6 kb upstream and d o w n s t r e a m of the transcription start site, respectively (Fig. 1A) . We prepared nuclei from control RD cells or from RD cells induced to express high level of ST3 (27) and these nuclei were exposed to increasing concentrations of DNase I. Following DNA extraction and digestion with Sac I, Southern blot analysis was performed using a genomic probe generated at the 5 ' -end of the 5.3 kb Sac I restriction fragment. Four DHS, including t w o constitutive DHS 1 and 3, and two inducible DHS 2 and 4 were identified within this 5.3 kb Sac I fragment and their position relative to t h e transcription start site is indicated in Fig. 1A . The position of the t w o proximal DHS1 and DHS2 is associated with the proximal ST3 p r o m o t e r and a thyroid responsive element (TRE, Fig. 1B ) (29) , respectively. I n addition, the distal inducible DHS4 further supports our previous finding in which we demonstrated that this site is associated with a C/EBP binding site (25) . An additional DHS3 was identified and w a s mapped to about 1.8 kb upstream of the transcription start site. T h e region including this DHS did not reveal any known consensus regulatory sequences.
Footprint analysis of the region near the DHS3
In order to precisely define the position of transcription factor binding sites associated with this DHS3, we performed footprinting experiments on two overlapping genomic fragments of 635 bp (from -2502 to -1 8 6 8 ) and 452 bp (from -1967 to -1516). Three different sequences w e r e identified by using the first probe ( Fig. 2A) . The first protected region, including a C/EBP element between bases -2169 and -2151, w a s observed only with nuclear extracts from TPA-differentiated cells 1 1 (lanes 7 to 9) and has been previously shown to mediate ST3 activation by TPA (25) . The second protected region between bases -2032 and -2014 was a RARE of the DR2 type (lanes 4 to 9) that has been shown t o be functional in the mouse ST3 gene promoter (35) . The last sequence including a TATAAA sequence at position -1972 suggested the presence of an additional promoter. However, this apparent TA-rich associated footprint was observed in the absence of nuclear extract (lane 1 to 3 ) and was not associated with any promoter activity (Fig. 5) . When t h e second probe including DHS3 was used (Fig. 2B) , a sequence b e t w e e n bases -1751 and -1713 was specifically protected in the presence of extract from RD cells expressing ST3 (lanes 7 to 9), but not with extracts from HeLa cells that do not express ST3. Although this protected region does not contain consensus sequences for any known DNA binding protein, a strong 5'-splice site sequence (exon-AGGTG/GTGA-intron) w a s identified about 170 bp downstream, suggesting the presence of a n additional exon. The position of each sequence revealed by footprint analysis relative to that of the DHS is illustrated in Fig. 1B .
Identification and expression of an additional ST3 transcript
In order to determine whether an additional ST3 mRNA w a s transcribed, semi-quantitative RT-PCR was performed on RNA extracted from either RD cells or human placenta with a 5' primer (XU112, nucleotides -1663 to -1637) upstream of the splice site and a 3 ' -p r i m e r (XV225) complementary to the 3'-UTR in the last exon of the ST3 gene. This 3'-primer was also used with a 5'-primer (nucleotides +75 to +97, YA160) designed from the first exon (E1α) of the α-ST3 transcript originally characterized. The resulting RT-PCR products were hybridized with a ST3 specific ST3 probe (Fig. 3A) . The expression of the α-ST3 transcript was found to be induced in RD cells in response to RA a n d higher levels of this transcript were observed in human placental tissue, further supporting previous observations (8, 27) . Interestingly, RT-PCR products were also observed with the 5'-primer (XU112) designed f r o m the genomic sequence upstream of the splice site, revealing t h e existence of an additional ST3 transcript (β-ST3). Like the α-ST3, this β -ST3 was found to be induced in RD cells in response to RA and to b e highly expressed in human placenta. Using the same primers, and u n d e r the same conditions, no β -transcript was detected in RNA extracted from two breast carcinoma samples or from HeLa cells, whereas t h e same RT-PCR product was observed with RNA extracted from TPA-stimulated human fibroblasts (data not shown). Additional PCR experiments were performed in order to clone and sequence the β-ST3. Its sequence was compared to that of the ST3 gene and that of the α -ST3 cDNA. This sequence analysis confirmed the use of the splice site observed at 170 bp downstream from the cell specific protected region described above, as well as the existence of an additional exon. The exon structure of the β-ST3, compared to that of the α-ST3 is illustrated i n Fig. 3B and shows that the two transcripts differ only by their 5'-exon of 130 bp and 178 bp for exon 1α and -1β, respectively.
Mapping of the β β β β -ST3 transcription start site and r e l a t i v e expression of the α α α α -and β β β β -ST3 transcripts In order to map the transcription start site of the β-ST3 transcript, w e have generated a construct (P2-β-ST3) in which the β-ST3 cDNA, including its whole first 5' exon, is placed directly downstream from i t s 5'-genomic flanking region (P2). This construct was transfected in COS-1 cells (Fig. 4A) . RNA was extracted from control COS-1 cells, from COS-1 cells transfected with the P2-β-ST3 construct, from RD cells treated w i t h RA and from human placental tissue. Reverse transcription w a s performed using a 3'-primer complementary to the second exon that is common to both α -and β-ST3 transcripts, as illustrated in Fig. 4B . T h e 5'-extension from this primer revealed a single band of 203 nucleotides specifically observed in transfected COS-1 cells (Fig. 4C, lane 7) and n o t in non transfected COS-1 cells (lane 6). The position of this b a n d corresponds to a G nucleotide (lane 5), as illustrated by sequencing t h e P2-β-ST3 construct, and represents the transcription start site (+2) of the β-ST3 (in bold, Fig. 6 ). Consistent with the expression of the β-ST3 transcript observed by RT-PCR (Fig. 3A) , the transcription start site w a s also mapped in human placental tissue (lane 1) and in RD cells (lane 8), as indicated by the presence of an identical band of 203 nucleotides. I n addition, as expected from the expression of the α-ST3 transcript previously reported in RD cells and in human placenta, the extension of the same primer also revealed a band of 155 nucleotides in these cells (lane 8) and in this tissue (lane 1). This band further confirms t h e position of the α-ST3 transcription start site, as initially mapped (29) . Its intensity relative to that of the 203 nucleotide band corresponding to the β-ST3, shows clearly that both ST3 transcripts are expressed a t similar levels in RD cells and human placenta. The β-ST3 transcription start site (+2) was found to be located 1720 bp upstream to that of t h e α-ST3 (+1) within the ST3 genomic sequence. The sequence of the first exon of the β-ST3 together with its 5'-flanking region is shown in Fig. 6 .
Characterization of an additional ST3 gene promoter
The transcription start site of the β-ST3 was mapped by using RNA extracted from COS-1 cells transfected with a β-ST3 cDNA under t h e control of a 59 bp sequence upstream of its first exon -1β (P2-β-ST3, Fig. 4C, lane 7) . This observation indicates the presence of a minimal promoter activity in the first 59 bp of the 5'-flanking region. W e therefore looked for basal and inducible promoter activity within a b o u t 1 kb of the exon-1β-5'-flanking region by performing transient transfection assays with a luciferase reporter gene (Fig. 5) . We found that all constructs including the sequence specifically protected in cells expressing ST3 are able to drive luciferase expression. Interestingly t h i s sequence is present in the 0.06-ST3-luc construct that represents a minimal sequence for which promoter activity is observed. In contrast, the 0.9-ST3-luc that does not contain this sequence was unable t o initiate luciferase expression, despite the presence of a TATAAA sequence at position -252 (Fig.6 ). As expected from previous studies (25, 36) , the addition of upstream sequences including the C/EBP element, confers promoter responsiveness to TPA or to increasing concentrations of the C/EBPβ factor.
Structure of the β β β
β -ST3 isoform The amino acid sequence deduced from the β-ST3 cDNA sequence (Fig.  6A ) was next analyzed and compared to that of the α-ST3. T h e expression of three α-ST3 protein species have been previously reported and their structures are illustrated in Fig. 7A . Like all MMPs, the α-ST3 is synthesized as an inactive proenzyme (PE) with a signal peptide and a propeptide. Its activation following the removal of t h e two N-terminal domains by proteolytic cleavage, generates an active o r mature secreted enzyme (E) of about 48 kDa (391 amino acids) consisting of the catalytic and the hemopexin-like domains. More recently, it was shown that further proteolytic cleavage of this α-ST3 mature enzyme generates an inactive 35 kDa ST3 protein of 299 a m i n o acids by an MMP-dependent mechanism (22) .
We have seen that the α -and β-ST3 transcripts are identical f r o m exons 2 to 8 and only differ at their 5' first exon (Fig. 3B) . As t h e 1 4 translation start site and the sequence encoding the signal peptide a r e present in the first exon of the α-ST3, these two features are excluded in the β-ST3 cDNA. Computer analysis of the β-ST3 cDNA sequence (Fig.  6A) revealed that the only ATG leading to an open reading f r a m e corresponds to the Met at position 130 within the frame of the α-ST3 proenzyme sequence. Translation from this ATG generates a protein of 359 amino acids with a predicted molecular weight of 40.5 kDa. T h e resulting β-ST3 isoform is therefore expected to be the equivalent of a truncated α -mature enzyme lacking the 32 N-terminal amino-acids of the catalytic domain.
The β-ST3 sequence was next compared with that of t h e previously characterized α-ST3. Fig. 6B shows a 400 bp sequence of t h e proximal promoter including, a DR1-RARE (at position -385) together with the first 450 bp of the α -ST3 cDNA including its 5'-specific exon 1α of 130 bp. Unlike the β-ST3, the α -ST3 has a short untranlated region of 22 bp preceding an encoding region of 129 amino acids that is specific to the α -ST3. This region encodes the signal peptide, the prodomain, t h e furine cleavage site and the first 32 amino acids of the catalytic domain. From the Met130 that corresponds to the translation start site of the β -ST3, the amino acid sequence is the same between both isoforms.
Western blot analysis of ST3 isoforms
The endogenous forms of ST3 expressed in RD cells were analyzed b y Western blot by using the monoclonal antibody 5ST4A9 (Fig. 7B) . T h e secretion of the α -ST3 mature enzyme (E) of about 48 kDa was induced in response to RA (compare lane 3 and 4). This mature α-ST3 was also detected by loading a high amount (about 100 µg) of proteins extracted from RA-stimulated cells (lane 5). An additional band of the same size (40 kDa) as that of the recombinant β-ST3 isoform (lane 2), was also detected (lane 5). Based on the amount of proteins analyzed electrophoretically, we estimate that the amount of extracellular ST3 is about twenty fold higher than its intracellular counterpart.
Since SL-6 cells have been shown to secrete high levels of ST3 (22), we next looked whether the 40 kDa ST3 isoform was also produced by these cells. The 48 kDa ST3 was secreted and processed by t h e s e cells into a 35 kDa protein (Fig. 7C, lane 1) that was strongly inhibited by the broad spectrum MMP inhibitor BB94 (lane 2). Interestingly, t h e 40 kDa ST3 was also detected in SL-6 cell lysates together with t h e by guest on January 1, 2018 http://www.jbc.org/ Downloaded from mature 48 kDa enzyme (lane 3). However, unlike the 35 kDa ST3, t h i s 40 kDa ST3 protein was not affected by the MMP inhibitor (lane 4) a n d is therefore not likely to be generated from the processing of the α-ST3 protein via an MMP-dependent mechanism. We therefore conclude t h a t the intracellular 40 kDa ST3 isoform detected with two different monoclonal antibodies in RD cells and SL-6 cells corresponds the β-ST3 isoform that is translated from the β -ST3 transcript.
Production of recombinant ST3 isoforms in E. coli and a n a l y s i s of their enzymatic activity. As the major part of the α -ST3 catalytic domain is present in the β-ST3-isoform, the question of its activity was addressed. The α-ST3 m a t u r e enzyme (E), the β-ST3 isoform and a mutated β-isoform (β-ST3m87) were expressed in E. coli and purified. The mutation was carried out b y substituting the Glu87 with Ala within the zinc binding site of t h e catalytic domain, a binding site (Fig. 8A) . The corresponding amino acid in the α -ST3 precursor form (Glu216) is essential for both the enzymatic activity and the tumor promoter effect of ST3 (33) . All the t h r e e recombinant proteins were analyzed by Coomassie blue-staining on t h e gel electrophoresis, by Western blotting (Fig. 8B ) and by N-terminal sequencing (data not shown). Their activity was determined by a quantitative assay previously characterized (32, 33) , that is based on t h e cleavage of α 1-antitrypsin, a member of the serpin family (7). Fig. 8C depicts the activity of α-ST3, used as a positive control. This activity is inhibited by a natural MMP inhibitor (TIMP-2) and by the synthetic MMP inhibitors BB94 (28) and RXPO3 (17) . The β-ST3 isoform w a s found to be as active as α-ST3 to cleave α 1-antitrypsin. This activity was also sensitive to the inhibitors to the same extent. Furthermore, t h e substitution of Glu87 with Ala abolished the activity of β-ST3, t h e r e b y excluding possible bacterial contaminants such as metalloenzymes t h a t would be inhibited by MMP inhibitors.
DISCUSSION
By looking to accessible sequences in the 5'-flanking region of t h e human ST3 gene we have mapped four DHS (Fig. 1) . These sites include DHS4, a region that was previously shown to be associated with t h e binding of a C/EBP element in cells induced to express ST3 by TPA (25) . The position of the two proximal DHS1 and DHS2 correspond to, respectively, the proximal ST3 promoter initially characterized and to a functionally conserved TRE (35) . Our footprint analysis near the t w o distal DHS3 and 4 revealed an additional RARE of the DR2 type and a cell specific protected region (Fig. 2) that turned out to be included in a second ST3 promoter (Fig. 3C ). This DR2-RARE is located 310 b p upstream of the β-ST3 transcript and is also functionally conserved i n the mouse ST3 gene promoter. Taken into account the induction of t h e β-ST3 transcript (Fig. 3B) , this element is therefore likely to mediate t h e induction of the observed 40 kDa isoform by RA (Fig. 6B and 7A ). Given that a proximal DR1-RARE mediates the transcriptional activation of t h e α-ST3 transcript in RD cells resulting in increased α-ST3 secretion (27), these observations demonstrate that both α -and β-ST3 are positively regulated by RA. In contrast to these RAREs, the TRE, the cell specific protected sequence and the C/EBP binding site are only present in t h e proximal or the distal gene promoter. A cell specific combination of factors binding to these cis-acting elements, together with alternative promoter usage may therefore accomplish a tissue specific regulation of each isoform. Further investigation will be required to determine which promoter and which ST3 isoform is activated in physiological o r pathological processes known to be associated with the expression of ST3.
The fact that regulatory sequences are well conserved in t h e mouse and the human ST3 genes suggests that the additional (P2) promoter and the β-ST3 transcript that we have identified may also b e conserved. However, when primer extension was carried out from t h e first or the second exon of the mouse ST3 gene, a single transcription start site was identified (35) . Furthermore, no additional p r o m o t e r activity was detected within a region of approximately 4 kb u p s t r e a m of the mouse ST3 gene (unpublished results). As the translation of t h e human β-ST3 isoform starts at the Met 130 residue, we looked for i t s 1 7 conservation within the N-terminal part of the catalytic domain of t h e mouse, rat, and Xenopus laevis ST3 protein sequences, as well as w i t h i n those of other MMPs (Fig. 9 ). Since no Met was found near this position in ST3 sequences from other species, we therefore conclude that t h e mechanism by which an additional promoter generates an N-terminal truncated ST3 isoform is human specific.
Nevertheless, a Met was found within the sequence of ten o t h e r human MMPs either at the same position as that of the human ST3 or i n close proximity (Fig. 9) , suggesting that other MMP isoforms could b e generated, as in the case of the human ST3. In this respect, it is interesting that several transcripts have also been reported for s e v e n MMPs including MMP-13 ( (41) and a soluble v e r s u s membrane shedding MT3-MMP is generated by alternative mRNA splicing (42). In addition, based on the lack of any signal peptide at t h e N-terminal end of MMP-23, it has been suggested that this MMP could function in an intracellular compartment (37) . Finally, more recently, a n intracellular gelatinase A protein has been shown to degrade troponin I (43). Taken together, these observations suggest that the additional MMP transcripts reported so far may also generate additional translation products. Whether other MMP isoforms could be g e n e r a t e d by alternative mRNA splicing and promoter usage that may regulate their subcellular localization deserves further investigation.
Previous studies (in situ hybridization or immunohistochemistry) have detected the expression of human ST3 in placental tissue or in t h e stroma of various types of carcinomas. In cultured cells, ST3 has b e e n detected in fibroblasts, RD cells, SL-6 cells (22, 27) , either by Northern blot analysis or by Western blotting the culture medium. The α -and β -transcripts only differ by their first exon and can not be distinguished by Northern blot analysis or in situ hybridization. Among cells a n d tissues previously shown to express ST3, the β-ST3 transcript w a s detected by RT-PCR (Fig. 3A) and primer extension analysis (Fig. 4C) i n cultured RD cells, fibroblasts and placental tissue, whereas it has n o t by guest on January 1, 2018 http://www.jbc.org/ Downloaded from been found in breast carcinomas. Accordingly, the 40 kDa β-ST3 isoform was detected in RD and also in SL-6 cells by Western blot analysis (Fig.  7) , whereas no β-ST3 was identified among the ST3 clones originally isolated from a breast cancer cDNA library (8) . These observations demonstrate that the two α -and β-ST3 isoforms are co-expressed i n several cell types, but that there is very little or no expression of the β -isoform in breast carcinomas. On the other hand, recent studies h a v e reported that ST3 is also expressed in macrophages and endothelial cells derived from atherosclerotic lesions (44) and in the endothelium of malignant colorectal tissues (45). Interestingly enough, the size of a ST3 isoform detected in macrophages is consistent with that of the β-ST3. I t is therefore tempting to speculate that in addition to the cells studied i n the present paper, the β-ST3 isoform is also expressed in other h u m a n cell types in vivo.
Unlike other MMPs, and unlike the mouse ST3, the human ST3 does not degrade the classical components of the ECM. This lack of activity of the human catalytic domain has been attributed to t h e presence of an alanine residue at position 235 since its substitution by a proline, an amino acid conserved in other MMPs including the mouse, rat and Xenopus laevis ST3, endow the human catalytic domain w i t h caseinolytic activity (5) . Based on this observation, it was previously suggested that among MMPs, the human ST3 has evolved to acquire additional functions. In this context, the intracellular localization of t h e β-ST3 isoform within a family of secreted or m e m b r a n e -t y p e proteinases is rather intriguing. On one hand, it highlights further t h e divergence of human ST3, but on the other hand, it suggests intracellular functions that might have not been envisaged within t h e MMP gene family. The fact that the β-ST3 was found to be as active a s the α -isoform (Fig. 8) is noteworthy. First of all, the N-terminal part of the MMP catalytic domain is usually defined by the end of t h e propeptide at the cleavage site. To the best of our knowledge, while t h e activity of C-terminal deleted recombinant MMPs has been well documented, this is the first time that an N-terminal truncated catalytic domain has been shown to be active. We can therefore speculate that Nterminal truncated forms of other mature MMPs may also be active. Second, the direct translation of the β−ST3 isoform into a constitutively active enzyme provides an appropriate mechanism by which the tightly regulated activation process required for the latent inactive MMP precusor form can be bypassed.
In summary, the ST3 gene has two promoters, each with its o w n unique exon 1 that is spliced to common exons 2 through 8. Transcripts from the downstream promoter (P1) generates the mRNA for the long isoform corresponding to the classical inactive α-ST3 isoform, w h e r e a s transcripts from the second distal promoter (P2) generates the mRNA for the short β-ST3 isoform that is directly translated as an active enzyme. Alternative splicing and promoter usage is a general mechanism commonly used for controlling the subcellular localization of number of proteins. In the context of proteinases, the identification of several transcripts for several MMP genes suggests that this mechanism is not be specific to human ST3 but may be a key mechanism by which MMPs are implicated in multiple functions.
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FOOTNOTES
The abbreviations used are: α 1-PI, α 1-proteinase inhibitor or α 1 -antitrypsin; bp, base pair; C/EBP, CCAAT/Enhancer Binding Protein; DHS, DNase I hypersensitive site; E, mature or active α-ST3 enzyme; ECM, extracellular matrix; IGF, Insulin-like growth factor; MMP: matrix metalloproteinase;
MT-MMP, Membrane-type MMP; PE, α−ST3 proenzyme or proform; RA, retinoic acid; RARE, RA responsive element; RT-PCR: reverse transcription polymerase chain reaction; serpin, serine proteinase inhibitor; ST3, stromelysin-3; TRE, thyroid h o r m o n e responsive element; UTR, untranslated region. was incubated with nuclear extracts from HeLa cells or RD cells. Both naked and bound DNA fragments were digested with increasing amounts of DNase I and samples were analyzed on a sequencing gel. T h e sequence of the protected regulatory elements is illustrated in bold a n d their position is indicated relative to the transcription start site. primer (XV225) complementary to the 3'-UTR of the ST3 gene was u s e d with both of these 5'-primers with RNA extracted from RD cells, RD cells treated with 1 µ M RA for three days or with RNA extracted from h u m a n placenta. The resulting RT-PCR products were hybridized to a ST3 cDNA specific probe and the 36B4 probe was used as an internal control f o r RNA. An additional PCR amplification was performed (with the p r i m e r s XU113 and XV226, as defined in materials and methods), in order t o clone and sequence the RT-PCR products. B. The structure of t h e classical α-ST3 cDNA (on top) is compared to that of the β-ST3 cDNA (bottom) deduced from sequence analysis (Fig. 6) . Boxed exons f r o m number 2 to 8 are common to both transcripts, whereas exon 1α (130 bp) and -1β (178 bp) are specific to the α -and the β-ST3 transcript, respectively. The relative positions of the primers used for the RT-PCR described in A are indicated below each transcript and their sequence is underlined in Fig. 6 . Note that the untranslated regions (open boxes), the open reading frame (grey boxes) and the size of the first exon (E-1β) of the β-ST3 were only defined once its transcription start site w a s mapped (Fig. 4) . A. The region from nucleotide position -500 to -1 corresponds to t h e genomic sequence upstream to the transcription start site (+1/G) of t h e β-ST3. This site is mapped in Fig. 4 and is located 1720 nucleotides upstream of the first exon of α-ST3. Regulatory elements associated with DH3 and 4 and identified by footprint analysis are underlined. T h e limit between the first exon specific to the β-ST3 cDNA and the second exon (E-1β/E2) is indicated at position +179. The deduced amino acid sequence is shown below the nucleotide sequence with an open reading frame of 359 amino acids. The sequence corresponding to the zincbinding site is boxed and the limit between the catalytic and t h e hemopexin domains is indicated between G143 and P144. Note the lack of the signal peptide, the prodomain and the furin cleavage site resulting from the absence of the first exon of the α -ST3 cDNA. B. The 400 bp 5'-flanking region of the α-ST3 is shown with the DR1-RARE at position -385. The first 448 nucleotides of the α-ST3 cDNA i s shown with its transcription start site (+1/A), its translation start site a t nucleotide position +23 and its specific first exon 1α (E1α) that is n o t present in the β-ST3. From the second exon (E2), the cDNA sequence is identical to that of the β-ST3 cDNA. Similarly, from the Met 130 t h a t corresponds to the translation start site of the β-ST3, the amino acid sequences of both α and β-ST3 isoforms are identical. Note that the first 129 amino acids corresponding to the signal peptide, the pro domain, t h e furine cleavage site and the N-terminal part of the catalytic domain a r e not present in the β-ST3 isoform. Sequences corresponding to 5'-primers or complementary to 3'-primers used in RT-PCR or primer extension analysis are underlined in A and B. Recombinant ST3 isoforms expressed in E. coli. were analyzed b y Coomassie blue staining after SDS PAGE (top) and by Western blotting (bottom) with the 5ST-4A9 antibody. C. Their catalytic activity w a s determined based on the capacity to inactivate α 1-antitrypsin, a n inhibitor of α -chymotrypsin. Both α-ST3 and β-ST3 inactivate α 1 -antitrypsin leading to α -chymotrypsin activity. These activities w e r e inhibited by the three MMP inhibitors BB94, RXPO3 and TIMP-2. The β -ST3m87 could not inactivate α 1-antitrypsin leading to the inhibition of α -chymotrypsin activity. by guest on January 1, 2018
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